Free Trial
NASDAQ:KROS

Keros Therapeutics (KROS) Stock Price, News & Analysis

Keros Therapeutics logo
$10.19 -0.60 (-5.56%)
Closing price 04:00 PM Eastern
Extended Trading
$10.18 -0.01 (-0.15%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Keros Therapeutics Stock (NASDAQ:KROS)

Key Stats

Today's Range
$9.71
$10.32
50-Day Range
$10.15
$12.02
52-Week Range
$9.71
$72.37
Volume
1.99 million shs
Average Volume
1.31 million shs
Market Capitalization
$413.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.33
Consensus Rating
Moderate Buy

Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Remove Ads

Keros Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

KROS MarketRank™: 

Keros Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 277th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Keros Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 8 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Keros Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Keros Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($4.74) to ($4.87) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Keros Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Keros Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Keros Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Keros Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.87% of the float of Keros Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Keros Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Keros Therapeutics has recently decreased by 3.83%, indicating that investor sentiment is improving.
  • Dividend Yield

    Keros Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Keros Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.87% of the float of Keros Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Keros Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Keros Therapeutics has recently decreased by 3.83%, indicating that investor sentiment is improving.
  • News Sentiment

    Keros Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Keros Therapeutics this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Keros Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.90% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Keros Therapeutics' insider trading history.
Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KROS Stock News Headlines

Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $42.33
Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
Wells Fargo Sticks to Their Buy Rating for Keros Therapeutics (KROS)
See More Headlines

KROS Stock Analysis - Frequently Asked Questions

Keros Therapeutics' stock was trading at $15.83 at the beginning of the year. Since then, KROS stock has decreased by 36.8% and is now trading at $10.0070.
View the best growth stocks for 2025 here
.

Keros Therapeutics, Inc. (NASDAQ:KROS) posted its quarterly earnings data on Wednesday, February, 26th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analysts' expectations of $37.32 million. Keros Therapeutics had a negative trailing twelve-month return on equity of 41.74% and a negative net margin of 27,890.94%.

Keros Therapeutics (KROS) raised $75 million in an initial public offering on Wednesday, April 8th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Top institutional investors of Keros Therapeutics include Vanguard Group Inc. (4.83%), Braidwell LP (4.68%), Darwin Global Management Ltd. (4.16%) and Alkeon Capital Management LLC (2.72%). Insiders that own company stock include Jennifer Lachey, Christopher Rovaldi and Keith Regnante.
View institutional ownership trends
.

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META) and Home Depot (HD).

Company Calendar

Last Earnings
2/26/2025
Today
3/31/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KROS
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$42.33
High Stock Price Target
$102.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+318.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
14 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-152,990,000.00
Net Margins
-27,890.94%
Pretax Margin
-27,890.94%

Debt

Sales & Book Value

Annual Sales
$3.55 million
Price / Cash Flow
N/A
Book Value
$11.09 per share
Price / Book
0.91

Miscellaneous

Free Float
31,231,000
Market Cap
$410.04 million
Optionable
Optionable
Beta
1.39
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:KROS) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners